Excalipoint debuts $68.7 million investment to advance its pipeline of TCE therapies. The company has six TCE therapies in development. Venture capital support was provided by Eli Lilly and Eisai. Excalipoint will strive to advance these therapies. Eli Lilly is a pharmaceutical company founded in 1876 and headquartered in Indianapolis.[2][4] In 2024, it had 46,913 employees and R&D expenditures of $10,990 million.[2] Collaborates on AI labs to accelerate drug development.[1]